(Q43502471)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

main subject

metastatic breast cancer

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Anna S Berghoff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Zsuzsanna Bago-Horvath

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Peter Dubsky

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Margaretha Rudas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Ursula Pluschnig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christoph Wiltschke

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Guenther G Steger

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christoph C Zielinski

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Rupert Bartsch

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

27 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

149-155

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

22 February 2020

cites work

1 reference

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

21 January 2018

1 reference

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

21 January 2018

1 reference

Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer

21 January 2018

1 reference

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials

21 January 2018

1 reference

Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.

21 January 2018

1 reference

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

21 January 2018

1 reference

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

An overview of prognostic factors for long-term survivors of breast cancer

21 January 2018

1 reference

Prognostic and predictive factors in breast cancer

21 January 2018

1 reference

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

21 January 2018

1 reference

Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial

21 January 2018

1 reference

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/TBJ.12070

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23350584%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference